Evaluation of Anthracycline Effects on NT-ProBNP Plasma Level in Children with Malignancy
Journal Title: Iranian Journal of Blood and Cancer - Year 2009, Vol 2, Issue 1
Abstract
Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. Anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. We measured the plasma levels of NT-proBNP to determine whether it might serve as a simple prognostic indicator of anthracycline-induced cardiotoxicity and to estimate the toxic levels of anthracyclines in children with malignancy treated with anthracycline containing regimens in Tehran’s Mofid hospital. Materials and Methods: This study was performed as a before and after clinical trial. Twenty-nine pediatric patients less than fifteen years old with newly diagnosed cancer were enrolled in this study. All patients received anthracycline-containing chemotherapy with 120 to 150 mg/m² in accumulative dose. Serial measurements of plasma NT-proBNP levels and echocardiographies were taken before onset of chemotherapy, simultaneous with accumulative dose of 120 to 150 mg/m² and two weeks after that dose. Results: Plasma levels of NT-proBNP were within normal limits before treatment and increased significantly after the mentioned accumulative dose (P=0.002) in 26 patients out of 29. All patients had normal echocardiograms and none developed heart failure during the two-year period of the study. Conclusion: NT-proBNP levels increases significantly after 120 to 150 mg/m² as accumulative dose in a subset of pediatric cancer patients. This increase is not associated with echocardiographic or clinical evidence of cardiac dysfunction. Longer follow-up of these patients is necessary to determine whether NT-proBNP can be used as an early and prognostic marker for anthracycline-induced cardiotoxicity and whether 120 to 150 mg/m² as accumulative dose of anthracycline is a safe dose or not.
Authors and Affiliations
Kourosh Goudarzi Pour, Shahin Shamsian, Fatemeh Vaziri, Roxana Aghakhani, Mohammad Taghi Arzanian
Keywords
Related Articles
- EP ID EP379772
- DOI -
- Views 78
- Downloads 0
Editorial
This article has no abstract.
Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia
This article has no abstract.
Tobacco Habits and Risk of Oral Cancer: A Retrospective Study in India
Background: It is suggested that various forms of tobacco use have some effects on diverse sites of head and neck to develop cancer. Material and Methods: The study examines data for oral cancer in male subjects, collect...
Brain MRI Findings in Children with Acute Lymphoblastic Leukemia
Background: Patients with leukemia are facing more complications in order to achieve longer survival. We aimed to evaluate the frequency of central nervous system abnormalities (CNS) on MRI of children with acute lymphob...
The effect of on demand and prophylactic therapeutic methods on quality of life among hemophilic children
Background: Treating a chronic disease such as hemophilia is to improve the symptoms and quality of life (QOL) of the patients. This study aimed to study the quality of life among hemophilic children and compare the qual...